Hospira 3Q11 3Q Revenues: $977 million (+3%) 3Q Loss: $88.9 million (earnings were $71.4 million in 3Q10) YTD Revenues: $3.0 billion (+4%) YTD Earnings: $204.6 million (-31%) Comments: Specialty Injectable Pharmaceuticals revenue was up 12% to $626.8 million in the quarter. Medication Management sales were $240.6 million (-5%). Other Pharma accounted for $109.3 million (-21%). Results in the quarter and YTD were impacted by certain quality actions taken in response to a FDA 2010 warning let...